Please assess the completion status of the following clinical trial:

Trial Title: Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female, \>40 years of age~2. Reported more than 7-8 moderate to severe hot flashes per day (average) or 50-60 moderate to severe hot flashes per week for at least 30 days prior~3. Spontaneous amenorrhea for at least 12 consecutive months~4. Amenorrhea for at least 6 months and meet the biochemical criteria for menopause~5. Bilateral salpingo-oophorectomy \>6 weeks with or without hysterectomy~Exclusion Criteria:~1. History of hypersensitivity or adverse reaction to paroxetine mesylate~2. Use of an investigational study medication within 30 days prior to screening or during the study~3. Concurrent participation in another clinical trial or previous participation in this trial~4. Family of investigational-site staff

- Gender: FEMALE
- Minimum Age: 41 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brisdelle (paroxetine mesylate) (Type: EXPERIMENTAL): Eligible subjects will be randomized to receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg.
- Placebo - Sugar Pill (Type: PLACEBO_COMPARATOR): Eligible subjects will be randomized to receive a sugar pill.

Based on this trial design, predict the completion outcome and termination type (if applicable).